Altre lingue Clinuvel Pharmaceuticals Limited Deutsche Boerse AG

Azioni

UR9

AU000000CUV3

Mercato chiuso - Deutsche Boerse AG Altri mercati azionari 14:38:09 07/06/2024			Variaz. 5gg	Var. 1 gen.
9,1 ^EUR	-0,44%		-5,41%	-8,30%

23/05	Clinuvel Pharmaceuticals collabora con Valentech Pharma per introdurre il farmaco per la PPE in America Latina	MT
14/03	Clinuvel Pharmaceuticals lancia un programma di riacquisto di azioni	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Clinuvel Pharmaceuticals Partners Valentech Pharma to Introduce EPP Drug in Latin America	23/05
Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%	29/04
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors	28/03
Clinuvel Pharmaceuticals Launches Share Buyback Program	14/03
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital.	14/03
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan.	14/03
Biotech-Unternehmen CLINUVEL launcht Photomedizin-Stiftung bei Event von Lady Gaga	07/03
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine	05/03
Clinuvel Reports Positive Results in SCENESSE Study	04/03
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	21/02
Clinuvel Pharmaceuticals Limited Announces Change to Registered Office	07/12
Clinuvel Doses First Patient in Phase 3 Trial of Vitiligo Treatment	18/10/23
Clinuvel Pharmaceuticals Limited Announces Board Changes	29/09/23
Clinuvel Pharmaceuticals Teams Up With Vitiligo Experts to Assess Scenesse	13/09/23
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023	29/08/23
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/08/23
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs	26/07/23
Clinuvel Pharmaceuticals Secures Patents for Melanocortins for Treatment of Central Nervous System Disorders	14/07/23
Clinuvel Pharmaceuticals Treats First Patient in Phase Two Stroke Trial	20/03/23
Clinuvel Pharmaceuticals Limited Announces Technical Note - CUV803 Study and AIS	20/03/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Clinuvel Pharmaceuticals Limited Deutsche Boerse AG

Azioni

UR9

AU000000CUV3

Altre lingue

Filtri